BerGenBio ASA
BRRGFOTCHealthcare
$97.09
+$0.00(+0.00%)
Market Cap$9.5B
P/E Ratioโ
52W High$97.09404
52W Low$0.025
BerGenBio ASA (BRRGF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BRRGF ยท earnings ยท updated Jun 9, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 19, 2025EPS Actual
-$0.07
Revenue
$0.00B
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 19, 2025
After Market Close
๐ฅ 6-Quarter EPS Beat Streak
BRRGF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP ยท Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
โ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| โ Q2 FY2026 | May 19, 2026 | -$80.13 | โ | โ | โ | $0.00B | โ |
| โ Q1 FY2026 | Feb 19, 2026 | -$69.29 | โ | โ | โ | $0.00B | โ |
| โ Q4 FY2025 | Nov 19, 2025 | โ | โ | โ | โ | โ | โ |
| โ Q3 FY2025 | Aug 19, 2025 | โ | -$0.07 | โ | $0.00B | โ | โ |
| โ Q2 FY2025 | May 23, 2025 | โ | -$0.06 | โ | $0.00B | โ | โ |
| โฒ Q1 FY2025 | Feb 26, 2025 | -$6.13 | -$0.21 | +96.6% | $0.00B | โ | โ |
| โฒ Q4 FY2024 | Nov 13, 2024 | -$8.12 | -$0.19 | +97.6% | โ | โ | โ |
| โฒ Q3 FY2024 | Aug 21, 2024 | -$7.50 | -$0.39 | +94.8% | โ | โ | โ |
Q2 FY2026
May 19, 2026
EPS Actual
โ
EPS Est.
-$80.13
EPS Surpr.
โ
Revenue
โ
Q1 FY2026
Feb 19, 2026
EPS Actual
โ
EPS Est.
-$69.29
EPS Surpr.
โ
Revenue
โ
Q4 FY2025
Nov 19, 2025
EPS Actual
โ
EPS Est.
โ
EPS Surpr.
โ
Revenue
โ
Q3 FY2025
Aug 19, 2025
EPS Actual
-$0.07
EPS Est.
โ
EPS Surpr.
โ
Revenue
$0.00B
Q2 FY2025
May 23, 2025
EPS Actual
-$0.06
EPS Est.
โ
EPS Surpr.
โ
Revenue
$0.00B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$6.13
EPS Surpr.
+96.6%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.19
EPS Est.
-$8.12
EPS Surpr.
+97.6%
Revenue
โ
Q3 FY2024
Aug 21, 2024Beat
EPS Actual
-$0.39
EPS Est.
-$7.50
EPS Surpr.
+94.8%
Revenue
โ
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2030 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Q2 FY2030 | $-0.79 | $-0.79 | $-0.79 | 1 |
| Q1 FY2030 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q4 FY2029 | $-1.15 | $-1.15 | $-1.15 | 1 |
| Q3 FY2029 | $-59.73 | $-59.73 | $-59.73 | 1 |
| Q2 FY2029 | $-79.03 | $-79.03 | $-79.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| โ Q3 FY2025 | Aug 19, 2025 | โ | $250.00 | $250.00 | +0.00% |
| โ Q2 FY2025 | May 23, 2025 | โ | $250.00 | $250.00 | +0.00% |
| โฒ Q1 FY2025 | Feb 26, 2025 | +96.6% | $250.00 | $250.00 | +0.00% |
| โฒ Q4 FY2024 | Nov 13, 2024 | +97.6% | $250.00 | $250.00 | +0.00% |
| โฒ Q3 FY2024 | Aug 21, 2024 | +94.8% | $250.00 | $250.00 | +0.00% |
| โฒ Q2 FY2024 | May 29, 2024 | +97.9% | $250.00 | $250.00 | +0.00% |
| โฒ Q1 FY2024 | Mar 6, 2024 | +95.1% | $250.00 | $250.00 | +0.00% |
| โฒ Q3 FY2023 | Sep 30, 2023 | +97.5% | $177.00 | $177.00 | +0.00% |
Q3 FY2025+0.00%
Report Date
Aug 19, 2025
EPS Beat/Miss
โ
Price Before
$250.00
Price After
$250.00
Q2 FY2025+0.00%
Report Date
May 23, 2025
EPS Beat/Miss
โ
Price Before
$250.00
Price After
$250.00
Q1 FY2025+0.00%
Report Date
Feb 26, 2025
EPS Beat/Miss
+96.6%
Price Before
$250.00
Price After
$250.00
Q4 FY2024+0.00%
Report Date
Nov 13, 2024
EPS Beat/Miss
+97.6%
Price Before
$250.00
Price After
$250.00
Q3 FY2024+0.00%
Report Date
Aug 21, 2024
EPS Beat/Miss
+94.8%
Price Before
$250.00
Price After
$250.00
Q2 FY2024+0.00%
Report Date
May 29, 2024
EPS Beat/Miss
+97.9%
Price Before
$250.00
Price After
$250.00
Q1 FY2024+0.00%
Report Date
Mar 6, 2024
EPS Beat/Miss
+95.1%
Price Before
$250.00
Price After
$250.00
Q3 FY2023+0.00%
Report Date
Sep 30, 2023
EPS Beat/Miss
+97.5%
Price Before
$177.00
Price After
$177.00
Avg Beat Reaction+0.00%
Beat Rate6 / 8 quarters
Largest Move+0.00% (Q3 FY2025)
Data: FMP /historical-price-eod/full ยท field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP)ย ย |ย ย Updated: Hourlyย ย |ย ย Surprise%: (Actual โ Estimate) / |Estimate| ร 100ย ย |ย ย Fiscal year: BRRGF ends December
BerGenBio ASA (BRRGF) most recently reported earnings on August 19, 2025 for Q3 FY2025, posting EPS of $-0.07 (in line with the analyst consensus of โ). BRRGF has beaten EPS estimates for 6 consecutive quarters. The next BRRGF earnings date is expected around September 1, 2026.
Each quarter, investors track BRRGF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BRRGF revenue tab โ
Earnings Glossary
EPS (Earnings Per Share)
Net income รท diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual โ Estimate) / |Estimate| ร 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual โฅ Estimate. Miss = Actual < Estimate. In-Line = within ยฑ1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BRRGF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BRRGF earnings ยท 4 questionsBerGenBio ASA's next earnings report is expected around September 1, 2026. BRRGF typically reports quarterly โ approximately every three months. The exact date is confirmed by the company 2โ4 weeks before the release. Time is currently TBD; BRRGF historically reports after market close (AMC).
BRRGF earnings datewhen is BRRGF earningsBRRGF next earnings datewhen does BRRGF report earningsBRRGF earnings calendar
โธ Source: FMP ยท BerGenBio ASA SEC filings ยท US GAAP ยท BerGenBio ASA SEC 10-K & 10-Q filings ยท US GAAP ยท Updated: Jun 9, 2026